Negative / Null Result ReportOpen accessMedicine· cited by 37

High-Dose Convalescent Plasma for Treatment of Severe COVID-19

Gil Cunha De Santis; Luciana Correa Oliveira de Oliveira; Pedro Manuel Marques Garibaldi; Carlos Eduardo L. Almado; Júlio Croda; Ghislaine G.A. Arcanjo; Erika Abdon Oliveira; Adriana Coracini Tonácio · 2022 · Emerging infectious diseases

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 1

Abstract by Gil Cunha De Santis; Luciana Correa Oliveira de Oliveira; Pedro Manuel Marques Garibaldi; Carlos Eduardo L. Almado; Júlio Croda; Ghislaine G.A. Arcanjo; Erika Abdon Oliveira; Adriana Coracini Tonácio, Emerging infectious diseases (2022) — licensed CC BY 4.0.

Read the full paper (open access)